Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
6.83% $7.04
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 353.08 mill |
EPS: | -2.63 |
P/E: | -2.68 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 50.15 mill |
Avg Daily Volume: | 0.155 mill |
RATING 2024-03-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.68 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.46x |
Company: PE -2.68 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.597 (-77.32%) $-5.44 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 6.50 - 7.62 ( +/- 7.99%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Warmuth Markus | Buy | 346 000 | Stock Option (Right to Buy) |
2024-01-02 | Wallace Owen B. | Buy | 119 000 | Stock Option (Right to Buy) |
2024-01-02 | Jones Jullian G | Buy | 79 000 | Stock Option (Right to Buy) |
2024-01-02 | Janku Filip | Buy | 121 000 | Stock Option (Right to Buy) |
2024-01-02 | Nickson Philip | Buy | 109 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.76 |
Last 98 transactions |
Buy: 57 206 836 | Sell: 164 598 288 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.04 (6.83% ) |
Volume | 0.147 mill |
Avg. Vol. | 0.155 mill |
% of Avg. Vol | 94.54 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:03 | sell | $4.74 | N/A | Active |
---|
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.